N/A N=20 Safety and Efficacy Study of HET Bipolar System for Treatment of Stage I and Stage II Hemorrhoids
Hemorrhoids, Internal
Primary: Number of Participants With Resolution of Symptoms — 18 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=300 War-Drill Model Guided Treatment of Hemorrhoids With Nimsai Herbal (NAJ)
Hemorrhoids · Hemorrhoidal Disease
Primary: Hemorrhoid Regression Rate — 117; 33 Participants — p=<0.001
N/A N=50 Open Hemorrohoidectomy Vs Transanal Hemorrhoidal Desarterialization in Hemorrhoids Grade III: The Effect on Symptoms
Hemorrhoids Third Degree
Primary: Hemorrhoidal Disease Symptom Score — 1; 7 units on a scale
Phase 2 N=103 Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids
Internal Hemorrhoids
Primary: Reduction in Swelling — 2.3; 2.0 scores on a scale — p=0.8918
N/A N=149 Comparison Study of Surgical Staplers for the Treatment of Hemorrhoids
Hemorrhoids
Primary: Intraoperative Bleeding — 32; 50 participants — p=0.0001
N/A N=288 Efficacy of the Third Eye Retroscope Auxiliary Imaging System
Colorectal Cancer
Primary: Increase (Percent) of Polyps Detected That Would Have Been Missed Without the Third Eye Retroscope (TER) — 13.2 percent of polyps
N/A N=448 Third Eye Retroscope Randomized Clinical Evaluation
Colorectal Neoplasms
Primary: Detection Rates for Adenomas and for Total Polyps — 160; 163; 78; 31 Polyps or adenomas detected
Phase 3 N=16,349 To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.
SARS-CoV-2 Infection · COVID-19
Primary: SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Interim…
Phase 1 N=120 Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
COVID-19 · COVID-19 Immunisation
Primary: Frequency of Any Medically-attended Adverse Events (MAAEs) — 7; 6; 5; 7 Participants
Phase 3 N=195 Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 1 — 0; 0; 8.3; 0 Percentage of participants
Phase 4 N=42 Endogenous Opioid Activity and Affective State in Insulin Resistant Women
Depression · Insulin Resistance · Metabolic Syndrome
Primary: Mu-opioid Receptor Binding Potential in Left Nucleus Accumbens, Resting State
N/A N=231 Diagnostic Precision of the AI Tool Dermalyzer to Identify Malignant Melanomas in Subjects Seeking Primary Care for Melanoma-suspected Cutaneous Lesions
Malignant Melanoma
Primary: Diagnostic Accuracy to Detect Melanoma — 20; 92; 1; 140 number of skin lesions
Phase 4 N=63 Safety and Efficacy of the Addition of Morphine Chloride to a Low Dose of Bupivacaine as Intradural Anaesthetic for the Removal Surgery of the Hemorrhoids
Surgical Remove of Hemorrhoids
Primary: Measurement of Time to Start the Anaesthetic Effect — 2.1; 1.6; 7.7; 4.7 minutes
N/A N=204 Use of Peanut Labor Ball Following Epidural Anesthesia
Pregnancy
Primary: Delivery Rate — 31; 21 participants
Phase 2 N=200 A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine
Respiratory Disorders
Primary: Number of Subjects Reported With Each Solicited Local Adverse Event (AE) (Any and Grade 3) Within Each Vaccination Schedule — 64; 64; 2; 1 Participants